As expected, neither adalimumab nor ustekinumab therapy had any effect on LPS-induced NF-κB translocation in psoriasis patients (Fig. 1b, c; Supplementary Fig. 3c and Supplementary Data 2). The gene discussed is NFKB1; the disease is psoriasis.